Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022093967 - COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY

Publication Number WO/2022/093967
Publication Date 05.05.2022
International Application No. PCT/US2021/056862
International Filing Date 27.10.2021
IPC
A61P 19/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 19/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
04for non-specific disorders of the connective tissue
A61P 19/08 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
C12Q 1/6827 2018.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6827for detection of mutation or polymorphism
A61K 31/203 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
203Retinoic acids
Applicants
  • THE JOHNS HOPKINS UNIVERSITY [US]/[US]
Inventors
  • CAO, Xu
Agents
  • GOETZ, Robert A.
Priority Data
63/106,70628.10.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY
(FR) COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE TROUBLES CARACTÉRISÉS PAR UNE ACTIVITÉ DE TGF-BÊTA
Abstract
(EN) Provided herein are compositions and methods directed to treating, delaying progression of, or ameliorating symptoms related to disorders characterized with TGF-β activity (e.g., disorders characterized with aberrant cartilage formation and/or osteoclast resorption (e.g., ankylosing spondylitis)) (e.g., spinal cord injuries) (e.g., fibrotic scar formation following spinal cord injury) through inhibition of TGF-β activity (e.g., thereby hindering and/or inhibiting aberrant cartilage formation and/or osteoclast resorption within joints, muscles, tendons, ligaments, connective tissue, and/or bones experiencing or at risk of experiencing ankylosis) (e.g., thereby inhibiting fibrotic scar formation following spinal cord injury).
(FR) L'invention concerne des compositions et des procédés pour traiter, retarder la progression de, ou atténuer des symptômes associés à des troubles caractérisés par une activité de TGF-β (par exemple, des troubles caractérisés par une formation de cartilage aberrant et/ou une résorption des ostéoclastes (par exemple, la spondylarthrite ankylosante)) (par exemple, des lésions de la moelle épinière)) (par exemple, la formation de cicatrice fibreuse suite à une lésion de la moelle épinière) par inhibition de l'activité de TGF-β (par exemple, en empêchant et/ou inhibant la formation de cartilage aberrant et/ou la résorption osseuse des ostéoclstes, dans des muscles, des tendons, des ligaments, le tissu conjonctif et/ou les os subissant ou à risque de souffrir de la spondylarthrite) (par exemple, par inhibition de la formation de cicatrice fibreuse suite à une lésion de la moelle épinière).
Latest bibliographic data on file with the International Bureau